Nucleic acid vaccines: Tasks and tactics

Immunologic Research

Volumn 24, Issue 3, 2001, Pages 225-244

  McKenzie, B S ^a   Corbett, A J ^a   Brady, J L ^a   Dyer, C M ^a   Strugnell, R A ^a   Kent, S J ^a   Kramer, D R ^a   Boyle, J S ^a   Lew, A M ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

DNA vaccines; Genetic vaccines; Immunization; RNA vaccines

Indexed keywords

ADJUVANT; CYTOKINE; DNA VACCINE; NUCLEIC ACID; VIRUS VACCINE; VIRUS VECTOR;

CELLULAR IMMUNITY; DRUG EFFECT; GENE TARGETING; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; REPLICON; REVIEW; VACCINE PRODUCTION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; BACTERIA; CPG ISLANDS; CYTOKINES; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; PLASMIDS; REPLICON; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRUSES;

EID: 0035173037     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:24:3:225     Document Type: Review

References (191)

1. Direct gene transfer into mouse muscle in vivo
2. High expression of naked plasmid DNA in muscles of young rodents
3. Conditions affecting direct gene transfer into rodent muscle in vivo
4. Sodium phosphate enhances plasmid DNA expression in vivo
5. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo
6. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse
7. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens
8. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization
9. Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine
10. Oral somatic transgene vaccination using attenuated S. typhimurium
11. Recent advances with recombinant bacterial vaccine vectors
12. Salmonella enterica serovar typhimurium-induced maturation of bone marrow-derived dendritic cells
13. Salmonella typhimurium invasion induces apoptosis in infected macrophages
14. Cross-presentation, dendritic cells, tolerance and immunity
15. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells
16. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route
17. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
18. Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells
19. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers
20. Molecular characterization and assembly of the needle complex of the Salmonella typhimurium type III protein secretion system
21. Alphavirus-based expression vectors: Strategies and applications
22. Alphavirus vectors for gene expression and vaccines
23. Subgenomic replicons of the fla vivirus Kunjin: Construction and applications
24. Alphaviruses - Vectors for the expression of heterologous genes
25. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
26. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A
27. Cancer therapy using a self-replicating RNA vaccine
28. Delivery Systems for Gene-based Vaccines
29. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
30. Sindbis virus DNA-based expression vectors: Utility for in vitro and in vivo gene transfer
31. Enhancing immune responses using suicidal DNA vaccines
32. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
33. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
34. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene
35. DNA and RNA-based vaccines: Principles, progress and prospects
36. Death mechanisms in cultured cells infected by Semliki Forest virus
37. Semliki Forest virus-based DNA expression vector: Transient protein production followed by cell death
38. Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs
39. Semliki Forest Virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
40. Immunologic and Virologic Status after 14 to 18 Years of Infection with an Attenuated Strain of HIV-1 - A Report from the Sydney Blood Bank Cohort
41. New viral vectors for HIV vaccine delivery
42. Immune responses to SIV mne envelope glycoproteins protect macaques from homologous SIV infection
43. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine
44. Recombinant vaccine-induced protection against the highly pathogenic SIV mac 251: Dependence on route of challenge exposure
45. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes
46. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
47. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
48. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
49. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
50. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
51. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys
52. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox viruses
53. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
54. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
55. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
56. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
57. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
58. DNA immunization: Induction of higher avidity antibody and effect of route on T cell cytotoxicity
59. The prime-boost strategy: Exciting prospects for improved vaccination
60. Vaccination with two different vaccinia recombinant viruses: Long-term inhibition of secondary vaccination
61. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses
62. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
63. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
64. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunisation with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice
65. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
66. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
67. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multi-epitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
68. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines
69. Modulation of cellular and humoral immune responses to a multi-epitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost
70. Disquisitions of Original Antigenic. Evidence in man
71. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes
72. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
73. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models
74. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun
75. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
76. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
77. CpG motifs in bacterial DNA trigger direct B-cell activation
78. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
79. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
80. A Toll-like receptor recognizes bacterial DNA
81. Immune activation by bacterial DNA: A new genetic code
82. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
83. Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells
84. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells
85. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses
86. Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor Activity
87. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
88. Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA
89. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
90. Contribution of CpG motifs to the immunogenicity of DNA vaccines
91. CpG motifs as immune adjuvants
92. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
93. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
94. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
95. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
96. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
97. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12
98. Vaccination with Allergen-IL-18 Fusion DNA Protects Against, and Reverses Established, Airway Hyperreactivity in a Murine Asthma Model
99. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1
100. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants
101. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines
102. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide
103. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles
104. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow derived cells
105. In vivo priming by DNA injection occurs predominantly by antigen transfer
106. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
107. Generation of MHC class 1-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells
108. Selected strategies to augment polynucleotide immunization
109. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines
110. The roles of MHC class 11, CD40, and B7 costimulation in CTL induction by plasmid DNA
111. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses
112. Antigen processing for amateurs and professionals
113. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge
114. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization
115. Chimeric lyssavirus glycoproteins with increased immunological potential
116. DNA immunization with minigenes: Low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination
117. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice
118. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge
119. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination
120. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice
121. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity
122. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization
123. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: Comparative studies of antibody and T-helper responses following genetic immunization
124. Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion
125. Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein
126. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo
127. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses
128. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization
129. Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice
130. Efficient expression of naked dna delivered intraarterially to limb muscles of nonhuman primates
131. Somatic transgene immunization with DNA encoding an immunoglobulin heavy chain
132. Strategies for improving responses to DNA vaccines
133. Production of polyclonal and monoclonal antibodies against CD54 molecules by intrasplenic immunization of plasmid DNA encoding CD54 protein
134. Intralymphatic immunization enhances DNA vaccination
135. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
136. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
137. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen
138. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep
139. Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions
140. Induction of HIV-1 specific mucosal immune responses by DNA vaccination
141. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses
142. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
143. Mucosal immunization with DNA vaccines
144. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA
145. Intraepithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs
146. Injection of plasmid DNA into the gastric mucosa induces mucosal and systemic immunity
147. Immunity obtained by gene-gun inoculation of a rotavirus DNA vaccine to the abdominal epidermis or anorectal epithelium
148. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles
149. Immunization of the female genital tract with a DNA-based vaccine
150. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene
151. Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle
152. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization
153. Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines
154. Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin
155. Mucosal and systemic antibody responses to a C4/V3 construct following DNA vaccination of rabbits via the Peyer's patch
156. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses
157. Targeting immune response induction with cochleate and liposome-based vaccines
158. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
159. Mucosal immunization with DNA-liposome complexes
160. Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization
161. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte- macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
162. Intranasal immunization with liposomes induces strong mucosal immune responses in mice
163. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
164. Biologically erodable microspheres as potential oral drug delivery systems
165. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: Effect of route of inoculation on immune response
166. Targeting of mucosal vaccines to Peyer's patch M cells
167. Microparticle targeting to M cells
168. A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression
169. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM 1 associated to cholera toxin B enhances mucosal immune responses
170. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
171. Mucosal immunization with DNA encoding influenza hemagglutinin
172. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization
173. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine
174. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
175. Use of live bacterial vaccine vectors for antigen delivery: Potential and limitations
176. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches
177. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes
178. Shigella flexneri IpaH(7.8) facilitates escape of virulent bacteria from the endocytic vacuoles of mouse and human macrophages
179. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier
180. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium
181. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector
182. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization
183. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes
184. Prime-boost immunization with dna vaccine: Mucosal route of administration changes the rules
185. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
186. Genetic immunization is a simple method for eliciting an immune response
187. Hepatitis and hepatitis A vaccine: A glimpse of history
188. Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines
189. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity
190. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
191. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1